Skip to main content
. 2022 Sep 2;13:937741. doi: 10.3389/fphar.2022.937741

FIGURE 7.

FIGURE 7

Intrathecal administration of AAV9-GFP-U6-m-Adcy1-shRNA (●) or AAV9-GFP-U6-scramble-shRNA (□) does not alter sciatic nerve C-fiber conduction properties. (A) Example of a compound action potential (CAP) recording from sciatic nerve of mouse. The (B) electrical thresholds, (C) maximum CAP amplitude, and (D) conduction velocity, were not significantly different between groups. Data presented as mean ± SEM with n = 10–20/group.